ChiRhoClin, Inc.

02/25/2026

Exciting developments are underway in gastroenterology, with secretin-stimulated endoscopic ultrasounds gaining prominence, as highlighted in the GI & Hep News article "Endoscopic ultrasound pushes beyond biopsy in diagnostics." These enhanced diagnostic methods are crucial for conditions ranging from chronic pancreatitis to early cancer detection, enabling healthcare providers to make timely treatment decisions.

For chronic pancreatitis, studies have demonstrated that "Secretin-stimulated EUS accurately predicted response to stent therapy in 81% of patients." While these findings are promising, further research is essential to establish this as the standard of care. In the realm of early pancreatic cancer detection, advancements are noteworthy. Healthcare providers can now perform a "liquid biopsy" by collecting fluid directly from the duodenum, eliminating the need to cannulate the pancreatic duct. This method, as noted by Dr. Wallace and colleagues, reduces the risk of pancreatitis associated with traditional endoscopic retrograde cholangiopancreatography (ERCP).

Consequently, more high-risk patients may be eligible for improved screening, as determined by their healthcare providers. When analyzing samples for both CA 19-9 and a methylated DNA marker panel (C13orf18, FER1L4, and BMP3), sensitivity and specificity reached 89% and 88%, respectively.

Secretin stimulation continues to unveil the complexities of the pancreas.
ChiRhoClin, Inc. is committed to supporting innovative research and diagnostic options for both patients and practitioners. For more information, visit www.chirhoclin.com or call 301-476-8388.

Bibliography Brunk, D. (2026, February 17). Endoscopic ultrasound pushes beyond biopsy in diagnostics.

GI & Hep News. Retrieved from https://lnkd.in/ed25p5TR Wallace, M. B., Majumder, S., Storz, P., & van Hooft, J. E. (2025, January 7). Emerging Diagnostic Indications for Endoscopic Ultrasound. Gastroenterology. doi: 10.1053/j.gastro.2025.07.028

https://news.gastro.org/issues/2026/february/endoscopic-ultrasound-pushes-beyond-biopsy-in-diagnostics/

American Gastroenterological Association's official newspaper

02/11/2026

May your love of pancreas function bring you great joy this Valentine's Day.

https://www.chirhoclin.com/resources/newsletter/love-thy-pancreas-february-newsletter-valentines-day-pancreas-friendly-chocolate-truffle-recipe/

11/21/2025

November is a special month for us for two important reasons: it’s Pancreatic Cancer and Disease Awareness Month, and it’s also a time to celebrate Thanksgiving.

We want to honor both, by raising awareness of pancreatic disease and by expressing our heartfelt gratitude to the loved ones, caregivers, patients, clinicians, and partners who walk this journey with us.

This year, we are especially thankful for the exciting progress being made in the fight against pancreatic cancer and disease. Our latest newsletter highlights some of these important developments—advances that bring real hope to patients and families and move us closer to better outcomes.

As we head into the holiday, we wish you and your families a safe, peaceful, and healthy Thanksgiving.
Here’s to hope, to progress, and to the people we are so grateful for.

Happy Thanksgiving.

https://www.chirhoclin.com/resources/newsletter/november-newsletter-freedom-from-pdac-early-detection-of-pancreatic-cancer-advancements/

10/20/2025

As we approach October, a month filled with significant events, we are gearing up for National Pancreatic Cancer Awareness Month in November. In the spirit of Halloween, we would like to highlight some exciting advancements in pancreatic cancer research.

For more information, check out our latest newsletter detailing these developments.

As the nights grow longer and pumpkins glow, researchers are lighting up the darkness around pancreatic disease with new tools and breakthroughs. By

07/17/2025

https://finance.yahoo.com/news/logicare3pl-partners-chirhoclin-inc-deliver-130000652.html

LogiCare3PL, a division of BioCare, Inc., is pleased to announce a strategic partnership with ChiRhoClin, Inc., a leader in pancreatic and gastrointestinal diagnostics. Effective July 14, 2025, LogiCare3PL will serve as the exclusive third-party logistics provider for ChiRhoStim® (Human Secretin fo...

05/04/2025

Welcome to DDW 2025!
Visit us at Booth #1815 and discover the power of precision pancreatic stimulation with Secretin. Learn how it enhances ERCP, EPFT, and MRCP procedures, and improves pancreatic fluid testing and collection.
Let’s talk about advancing diagnostic accuracy for pancreatic disease—and how we can support your practice.

03/28/2025

In 2025, our marketing campaign centers on the elegant and clinically powerful way human secretin stimulates the pancreas—enabling multiple diagnostic approaches to evaluate pancreatic function and detect disease, including pancreatic cancer.

If you’re looking to diagnose the pancreas with accuracy and confidence, secretin is the key.

We’re excited to revisit a theme from one of our most memorable campaigns: “Turn on the Pancreas.” Now, with enhanced visuals and a renewed focus on Precision Pancreatic Stimulation (PPS), we’re blending our legacy with innovation to reflect today’s advancements in precision medicine.

ChiRhoStim® (Human Secretin for Injection) is designed to support your clinical decisions with clarity, confidence, and precision.

We look forward to partnering with you to advance precision diagnostics and improve patient outcomes.

Sincerely,

Skip Purich

C.E.O

In 2025, our marketing campaign centers on the elegant and clinically powerful way human secretin stimulates the pancreas—enabling multiple diagnostic

02/28/2025

ChiRhoClin Stands Together for Rare Disease Day

On this Rare Disease Day, ChiRhoClin proudly stands with patients, caregivers, and healthcare professionals to raise awareness and support for those affected by rare diseases, including gastrinoma and other rare pancreatic disorders. We recognize the challenges faced by individuals living with these conditions and remain committed to advancing research, education, and innovative solutions that improve diagnosis and treatment.

Together, we advocate for increased awareness, earlier detection, and better patient outcomes. No one should face a rare disease alone—ChiRhoClin stands with the rare disease community today and every day.

Gastrinoma is a rare neuroendocrine tumor that secretes excess gastrin, leading to Zollinger-Ellison syndrome (ZES). This condition is characterized by

10/26/2024

https://www.linkedin.com/posts/chirhoclin-inc%2E_chirhoclin-will-be-exhibiting-at-the-american-activity-7255758024105979904-_wHt?utm_source=share&utm_medium=member_ios

ChiRhoClin will be exhibiting at the American College of Gastroenterology conference in Philadelphia this year. Booth # 775. We look forward to connecting…